Clinical Trial Update: Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of ramelteon (TAK-375) for sublingual administration in adults with Bipolar I disorder was terminated; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Ramelteon (ramelteon)

Snippet

Sponsor: Takeda | Conditions: Bipolar Disorder | Phase 3 | Status: TERMINATED | Results posted: 2016-03-16